Nuvalent, INC 8-K filings

Nuvalent announced its first quarter 2024 financial results, highlighted progress in its clinical trials, and reiterated its goal of a potential first product approval in 2026.

Nuvalent announced pipeline advancements, including FDA breakthrough therapy designation for NVL-520, and reported its fourth quarter and full year 2023 financial results, highlighting a strong cash position expected to fund operations into 2027.